Kidney Cancer UK

02/06/2026

We're proud to be supporting the IKCC campaign 💚

This year's focus is on emotional wellbeing. An often-overlooked aspect of living with kidney cancer.

According to the 2025 IKCC Global Patient Survey - 85% of kidney cancer patients experience an impact on their emotional wellbeing. Yet many never discuss how they're feeling with their family, friends, or healthcare team.

To help change that, the IKCC has created a simple wellbeing check-in tool, encouraging patients to reflect on their mental health and start important conversations about the emotional impact of kidney cancer.

No one should have to face the emotional challenges of kidney cancer alone 💚

Take a moment to check in 🔗https://www.worldkidneycancerday.org/wp-content/uploads/2026/04/WKCD26_PDF_EN.pdf

01/06/2026

NEWS: New results from the international RAMPART trial have shown that a combination of immunotherapy drugs given after kidney cancer surgery can significantly reduce the risk of the cancer returning.

Researchers found that patients receiving durvalumab and tremelimumab were more likely to remain cancer-free three years after treatment compared to those receiving standard monitoring alone. The greatest benefit was seen in patients at the highest risk of recurrence.

For many people affected by kidney cancer, the fear of recurrence can be overwhelming. Advances like this offer real hope that more patients may be able to stay cancer-free for longer following surgery.

While further research is ongoing, these findings mark an important step forward in improving outcomes for people living with RCC (renal cell carcinoma), the most common form of kidney cancer.

Read the full article here 🔗 https://www.icr.ac.uk/about-us/icr-news/detail/combination-immunotherapy-significantly-reduces-kidney-cancer-recurrence-after-surgery

Combination immunotherapy significantly reduces kidney cancer recurrence after surgery

28/05/2026

Join us this June for Walkies 100! 🐾

Grab your lead, bring your furry friend, and enjoy a fun walk 💚

How to join in:
1) Sign up 🔗 https://www.justgiving.com/create-page/target?sessionId=4857bf2
2) Set your fundraising target.
3) Launch your page.
4) Share your page with friends and family.

23/05/2026

Walkies 100k! 🐾

Grab your doggy scarf from our shop - all profits go to supporting kidney cancer patients across the UK.

Shop here 🔗 https://kidneycanceruk.printmykit.co.uk/shop/view_product/23884791/Kidney-Cancer-UK-Dog-Bandana

22/05/2026

Charlie is taking on the Edinburgh Marathon 💪

"The photo above is of my grandad running the Edinburgh Marathon back in 1983.

Being able to run the same race all these years later, in his memory, feels incredibly special and personal to me.

On top of that, this marathon represents something deeper in my own life. I’ve spent years dealing with chronic foot pain, and for a long time, running felt completely out of reach.

To be in a position where I can train for and run a marathon is something I'm very grateful for. The marathon is not just for me, but for my grandad too.

I’m raising money for Kidney Cancer UK to help support others affected by this disease.

If you’re able to donate, it would mean a lot. Every contribution, big or small, makes a difference. Thank you."

If you're able to, please support Charlie's fundraiser 🔗 https://www.justgiving.com/page/edinburgh-marathon-charlie

21/05/2026

Join in our Walkies event this June! 🐾

Walk 100km with your furry friend, and raise vital funds for kidney cancer patients across the UK!

Sign up today 🔗 https://www.justgiving.com/create-page.

21/05/2026

NEWS: Personalised kidney cancer care 💚

Researchers have developed the new PREDICT-Kidney online tool to help patients and healthcare professionals make more informed decisions about follow-up care after kidney cancer surgery.

The tool was co-designed with patients, the public, and healthcare professionals across the UK, ensuring that patient voices were at the heart of its development. It provides personalised estimates of recurrence risk and presents information in clear visual formats to support shared decision-making.

This is an important step towards more transparent, patient-centred care and empowering people with the information they need after treatment.

Read more here 🔗

Kidney Cancer, renal cell carcinoma, PREDICT-Kidney Online Tool, Kidney Cancer Follow-up Care, personalised follow-up care after kidney cancer surgery.

20/05/2026

NEWS: Encouraging new research for people living with non-clear cell kidney cancer 💚

New data presented at ASCO GU 2026 showed that a combination of fruquintinib and serplulimab demonstrated promising results as a first-line treatment for metastatic or unresectable non-clear cell renal cell carcinoma (nccRCC).

The trial reported strong disease control rates and encouraging responses in patients, with researchers also noting that the treatment was generally well tolerated. While further studies are still needed, these findings offer hope for improved treatment options for a type of kidney cancer that has historically had fewer targeted therapies available.

Read more here 🔗

ASCO GU 2026 fruquintinib + serplulimab as first line therapy in metastatic or unresectable non-clear cell RCC, VEGFR inhibitor.

19/05/2026

NEWS: Promising new research for kidney cancer patients 💚

Results from the FASTRACK II trial have shown that a highly targeted form of radiotherapy called SABR (stereotactic ablative body radiotherapy) could offer a safe and effective treatment option for some people with localised kidney cancer who are unable to have surgery.

The long-term findings showed excellent cancer control rates with very few serious side effects, giving more options to patients who may previously have had limited treatment options.

While surgery remains the standard treatment for many people with kidney cancer, studies like this are a step forward in expanding future treatment possibilities and improving patient choice.

Read more here 🔗

Long-Term FASTRACK II Data Support SABR for Primary Kidney Cancer / ESTRO, ESTRO 2026, FASTRACK II, Headlines, kidney cancer, Radiation Oncolog, radiotherapy